Background:

Arylamine N-acetyltransferases (NAT-1 and NAT-2) catalyze N- or O-acetylation of heterocyclic and arylamine substrates in the detoxification of a wide array of drugs. Certain alleles causing high N-acetyltransferase activity have been associated with colon and urinary bladder cancers, as NATs also bioactivate several known carcinogens. Both NAT-1 and NAT-2 are cytoplasmic proteins and play an active role in the detoxification of many arylamine and hydrazine drugs. N-acetylation polymorphism is determined by the level of NAT activity in liver tissues, and has been linked to the action and toxicity of drugs that contain amines. Human NAT-1 is the functional homolog of rodent NAT-2, while human NAT-2 is the functional homolog of rodent NAT-1.

Specificity:

NAT1 polyclonal antibody detects endogenous levels of NAT1 protein.

Alternative names:

Arylamine N-acetyltransferase 1; Arylamide acetylase 1; Monomorphic arylamine N-acetyltransferase; MNAT; N-acetyltransferase type 1; NAT-1; NAT1; AAC1

Species reactivity:

Human,Mouse

Host:

Rabbit

Ig type:

Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2

Immunogen:

Recombinant full length Human NAT1.

Purification & Purity:

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).

Molecular weight:

~34 kDa

Applications:

WB IHC

Usage:

WB 1:500 - 1:2000 IHC 1:50 - 1:100

Storage:

Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Precautions:

For research use only, not for use in diagnostic procedure.

More info:

Email: info@sobekbio.com

Orders:

Email: orders@sobekbio.com